• Nature Immunology publication highlights importance of discovery underpinning Sofra platform
• New understanding of how immune system works
• Independent US expert endorses research breakthrough

Noxopharm Limited (ASX:NOX) is pleased to announce the publication of a scientific paper detailing the breakthrough science underlying the Sofra platform in the prestigious medical journal Nature Immunology. The paper, titled '2'-O-Methyl-guanosine RNA fragments antagonize TLR7 and TLR8 to limit autoimmunity', describes a groundbreaking discovery of a novel anti-inflammatory mechanism crucial for safeguarding against autoimmune disorders. The lead author is Professor Michael Gantier of Hudson Institute of Medical Research, Noxopharm's exclusive strategic partner in the development of the technology. The publication in Nature Immunology, a top-ranking peer-reviewed journal for primary research in immunology, is clear evidence that Noxopharm is building the Sofra platform on very solid foundations. The sophisticated research has opened the door to the development of promising new drugs for diseases with a strong inflammatory component, such as lupus, psoriasis, diabetes, and rheumatoid arthritis. Professor Arthur Krieg, a world-leading expert on oligonucleotides and the immune system, has recognized the breakthrough research presented in the paper, stating that it 'has transformed our understanding of how immune sensors for viral infections are normally blocked to prevent autoimmunity' and provides a pathway to support the development of new medicines.

Following the publication of the paper, Noxopharm expects even greater interest in its work as the word spreads about the Sofra technology and its potential applications in a wide range of diseases related to the immune system, such as rheumatoid arthritis, lupus, and diabetes, as well as other diseases like cancer.